Standout Papers

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma 2007 2026 2013 2019 6.2k
  1. Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma (2009)
    Tony Mok, Yi‐Long Wu et al. New England Journal of Medicine
  2. MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling (2007)
    Jeffrey A. Engelman, Kreshnik Zejnullahu et al. Science
  3. Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations (2013)
    Lecia V. Sequist, James Chih‐Hsin Yang et al. Journal of Clinical Oncology
  4. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer (2016)
    Tony Mok, Yi‐Long Wu et al. New England Journal of Medicine
  5. First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer (2014)
    Benjamin Solomon, Tony Mok et al. New England Journal of Medicine
  6. Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer (2017)
    Solange Peters, D. Ross Camidge et al. New England Journal of Medicine
  7. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2018)
    David Planchard, Sanjay Popat et al. Annals of Oncology
  8. Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS) (2011)
    Masahiro Fukuoka, Yi‐Long Wu et al. Journal of Clinical Oncology
  9. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial (2008)
    Edward S. Kim, Vera Hirsh et al. The Lancet
  10. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial (2017)
    Yi‐Long Wu, Ying Cheng et al. The Lancet Oncology
  11. Non-small-cell lung cancer (2015)
    Cesare Gridelli, Antônio Rossi et al. Nature Reviews Disease Primers
  12. Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 (2015)
    James Chih‐Hsin Yang, Lecia V. Sequist et al. The Lancet Oncology
  13. Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial (2019)
    Martin Reck, Tony Mok et al. The Lancet Respiratory Medicine
  14. First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer (2020)
    Alice T. Shaw, Todd M. Bauer et al. New England Journal of Medicine
  15. Management of non-small-cell lung cancer: recent developments (2013)
    Martin Reck, David F. Heigener et al. The Lancet
  16. Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis (2016)
    Chee Khoon Lee, Johnathan Man et al. Journal of Thoracic Oncology
  17. De-novo and acquired resistance to immune checkpoint targeting (2017)
    Nicholas Syn, Michele W.L. Teng et al. The Lancet Oncology
  18. Lengthening and shortening of plasma DNA in hepatocellular carcinoma patients (2015)
    Peiyong Jiang, K.C. Allen Chan et al. Proceedings of the National Academy of Sciences
  19. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133) (2021)
    Stephen V. Liu, Martin Reck et al. Journal of Clinical Oncology
  20. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial (2017)
    Alice T. Shaw, Tae Min Kim et al. The Lancet Oncology
  21. Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study (2020)
    Tony Mok, D. Ross Camidge et al. Annals of Oncology
  22. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: overall survival data from the phase IIb LUX-Lung 7 trial (2017)
    Luis Paz‐Ares, E.H. Tan et al. Annals of Oncology
  23. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma (2017)
    Chee Khoon Lee, Johnathan Man et al. JAMA Oncology
  24. Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy (2015)
    Tony Mok, Yi‐Long Wu et al. Clinical Cancer Research
  25. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3) (2018)
    Yi‐Long Wu, Myung‐Ju Ahn et al. Journal of Clinical Oncology
  26. Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2023)
    Lizza Hendriks, Keith M. Kerr et al. Annals of Oncology
  27. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer and EGFR-Activating Mutations (2018)
    Tony Mok, Ying Cheng et al. Journal of Clinical Oncology
  28. MET Amplification and Exon 14 Splice Site Mutation Define Unique Molecular Subgroups of Non–Small Cell Lung Carcinoma with Poor Prognosis (2016)
    Joanna H. Tong, Sai F. Yeung et al. Clinical Cancer Research
  29. Overcoming therapy resistance in EGFR-mutant lung cancer (2021)
    Antonio Passaro, Pasi A. Jänne et al. Nature Cancer
  30. Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study (2019)
    D. Ross Camidge, Rafał Dziadziuszko et al. Journal of Thoracic Oncology
  31. Final Overall Survival Analysis From a Study Comparing First-Line Crizotinib Versus Chemotherapy in ALK-Mutation-Positive Non–Small-Cell Lung Cancer (2018)
    Benjamin Solomon, Dong‐Wan Kim et al. Journal of Clinical Oncology
  32. Nivolumab Versus Docetaxel in a Predominantly Chinese Patient Population With Previously Treated Advanced NSCLC: CheckMate 078 Randomized Phase III Clinical Trial (2019)
    Yi‐Long Wu, Shun Lü et al. Journal of Thoracic Oncology
  33. Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up (2023)
    Lizza Hendriks, Keith M. Kerr et al. Annals of Oncology
  34. Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study (2022)
    Melissa L. Johnson, Byoung Chul Cho et al. Journal of Clinical Oncology
  35. Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies (2022)
    Antonio Passaro, Julie R. Brahmer et al. Journal of Clinical Oncology
  36. Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study (2022)
    Gilberto de Castro, Iveta Kudaba et al. Journal of Clinical Oncology
  37. Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study (2022)
    Benjamin Solomon, Todd M. Bauer et al. The Lancet Respiratory Medicine
  38. Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer (2023)
    Mark A. Socinski, Robert M. Jotte et al. JAMA Oncology
  39. Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study (2024)
    Benjamin Solomon, Geoffrey Liu et al. Journal of Clinical Oncology
  40. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial (2023)
    Juliann Chmielecki, Tony Mok et al. Nature Communications

Immediate Impact

4 by Nobel laureates 21 from Science/Nature 157 standout
Sub-graph 1 of 17

Citing Papers

Cancer biomarkers: Emerging trends and clinical implications for personalized treatment
2024 Standout
Perioperative Pembrolizumab for Early-Stage Non–Small-Cell Lung Cancer
2023 Standout
16 intermediate papers

Works of Tony Mok being referenced

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
2023 Standout
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)
2011 Standout
and 18 more

Author Peers

Author Last Decade Papers Cites
Tony Mok 38626 34880 12185 15477 671 55.0k
Pasi A. Jänne 39885 35323 13408 25164 645 60.0k
Bruce E. Johnson 28871 29340 9567 20418 411 49.7k
Frances A. Shepherd 32265 30783 7188 11958 662 48.5k
Jaap Verweij 21972 27869 5580 13557 619 54.4k
Roy S. Herbst 25944 31201 9057 16614 573 49.6k
Josep Tabernero 14187 33324 8631 14088 1.1k 49.1k
Mark G. Kris 37830 35614 9225 16418 652 61.0k
Bernard Escudier 26197 14176 13763 22473 712 40.8k
Vincent A. Miller 30167 29326 10353 15829 476 44.8k
John D. Hainsworth 12105 21144 5167 9981 623 36.4k

All Works

Loading papers...

Rankless by CCL
2026